Tak-659
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer CenterPhase 1Dormant
C
33/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 18/ 100
- Competitive Position
- 81/ 100
Competitive context
124 Active assets in the Advanced Malignant Solid Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Palbociclib National Cancer Institute (NCI) | Phase 2 | BB |
Olaparib National Cancer Institute (NCI) | Phase 2 | BB |
Nivolumab National Cancer Institute (NCI) | Phase 2 | BB |
Carboplatin OHSU Knight Cancer Institute | Phase 2 | B |
Vinorelbine OHSU Knight Cancer Institute | Phase 2 | B |
View all 50 →
Same molecule, other indications
Tak-659 is also rated in:
high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangementDormant
C
Indicative ·
33 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →